About Us  |  Contact Us  |  Español
VNA of Care New England
VNA of Care New England

Kcentra Approved to Stop Severe Bleeding in Heart Patients

Can be given faster than plasma
TUESDAY, April 30 (HealthDay News) -- Kcentra (prothrombin complex concentrate, human) has been approved by the U.S. Food and Drug Administration to treat severe acute bleeding in adults after administration of the anti-clotting drug warfarin and similar products.
Blood plasma is the only other product approved for this use, the FDA said in a news release, but plasma requires blood typing and may require thawing. This means Kcentra usually can be administered more quickly than plasma to stop major bleeding.
Warfarin and similar anticoagulants are typically prescribed in cases of atrial fibrillation (irregular heartbeat) and for people with an artificial heart valve, the FDA said.
Kcentra will carry a boxed label warning that it may increase users' risk of blood clots. Made from the pooled plasma of screened donors, it's processed to minimize recipients' risk of acquiring viruses and other germs, the agency said.
In a study of 216 people who had been receiving anticoagulation therapy and who developed major bleeding, Kcentra was found to be as effective as plasma in treating the problem, the FDA said.
The drug is produced by the German company CSL Behring.
More information
To learn more about this approval, visit the FDA (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm350026.htm ).
Health Headlines
FDA Approves HPV Test as Initial Screen for Cervical CancerView in a lightbox
FDA Proposes E-Cigarette RegulationsView in a lightbox
FDA Reconsiders Behavior-Modifying 'Shock Devices'View in a lightbox
Genetic Code of Tsetse Fly May Help Fight Sleeping SicknessView in a lightbox
Workplace Ladder Falls a Major Cause of Deaths, Injuries: CDCView in a lightbox
VNA of Care New England
© 2011 Site Index | Disclaimer | Legal Notices